CLINICAL TRIAL: Celyad Starts New Dosing with Natural Killer Cells in Early Study for Myeloma
Dr. Christian Homsy, CEO of Celyad, commented: “We are pleased to have enrolled the first patient in the fourth dose level cohort of this study on track and are encouraged that no adverse safety signals have been observed so far for the nine patients already treated with NKR-2. We are actively working on the recruitment of the two next patients for this new dose level and we look forward to the data that are expected in the next few months” Dr. Frédéric Lehmann, Head of Immuno-Oncology at Celyad: «The infusion of the 10th patient demonstrates good progress in our first-in-human NKR-2 Phase I/IIa study. This technology has great potential in multiple cancer indications and we look forward to completing this Phase I/IIa and moving to the next stage in clinical development.”About Celyad’s NKR-T program NKR stands for Natural Killer Cell Receptor. NKG2D CAR T-cells are now called NKR-2 T-cells and the product development name is NKR-2.
Using the human Natural Killer cell receptor, unlike traditional CAR technologies, NKR-2 has the potential to:
- Bind to 8 different ligands that are expressed by a vast majority of cancer cells, both hemaetological and solid malignancies.
- Target and kill tumors as well as the blood vessels that feed them and also express the ligands of the NKG2D receptor.
- Act on the immunosuppressive microenvironment within tumors resulting in the inhibition of the mechanisms which enable tumor to evade the immune system.
- Induce adaptive auto-immune response resulting in the creation of a long term cell memory against the targeted tumor.